JP2003533468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003533468A5 JP2003533468A5 JP2001583736A JP2001583736A JP2003533468A5 JP 2003533468 A5 JP2003533468 A5 JP 2003533468A5 JP 2001583736 A JP2001583736 A JP 2001583736A JP 2001583736 A JP2001583736 A JP 2001583736A JP 2003533468 A5 JP2003533468 A5 JP 2003533468A5
- Authority
- JP
- Japan
- Prior art keywords
- matrix material
- protein matrix
- protein
- solvated
- compressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 48
- 239000011159 matrix material Substances 0.000 description 38
- -1 silk Proteins 0.000 description 9
- 210000001519 tissues Anatomy 0.000 description 9
- 229940089114 Drug Delivery Device Drugs 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 230000003187 abdominal Effects 0.000 description 3
- 230000001464 adherent Effects 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N Sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000789 fastener Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NGXDNMNOQDVTRL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(4-azido-2-nitroanilino)hexanoate Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1NCCCCCC(=O)ON1C(=O)CCC1=O NGXDNMNOQDVTRL-UHFFFAOYSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- WXMFWWZIJLIMLP-UHFFFAOYSA-N 2-[3-(2-carboxyphenoxy)propoxy]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1OCCCOC1=CC=CC=C1C(O)=O WXMFWWZIJLIMLP-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N 2-hydroxyethyl 2-methylacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- CEBRPXLXYCFYGU-UHFFFAOYSA-N 3-methylbut-1-enylbenzene Chemical compound CC(C)C=CC1=CC=CC=C1 CEBRPXLXYCFYGU-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229940088710 Antibiotic Drugs 0.000 description 1
- 229960005348 Antithrombin III Drugs 0.000 description 1
- 102000004411 Antithrombin-III Human genes 0.000 description 1
- 108090000935 Antithrombin-III Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229950003499 FIBRIN Drugs 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 229940012952 Fibrinogen Drugs 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 210000003709 Heart Valves Anatomy 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 210000003041 Ligaments Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 102000003505 Myosin family Human genes 0.000 description 1
- 108060008487 Myosin family Proteins 0.000 description 1
- RQUGVTLRYOAFLV-UHFFFAOYSA-N N-(4-aminobutyl)-4-azido-2-hydroxybenzamide Chemical compound NCCCCNC(=O)C1=CC=C(N=[N+]=[N-])C=C1O RQUGVTLRYOAFLV-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001225 Polyester resin Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- BTVGHQASHWCGHI-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O.CCCC(O)=O BTVGHQASHWCGHI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 230000002921 anti-spasmodic Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001889 chemoattractant Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001484 poly(alkylene) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002492 poly(sulfones) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 塗布可能なフィルムを形成するように１又は複数の生物適合性溶媒と組み合わされた１又は複数の生物適合性タンパク質材料を含んで成る溶媒化され圧縮されたタンパク質マトリックス材料であって、前記の塗布可能なフィルムが部分的に乾燥され、接着体に形成され、そしてバルク水を減少せしめ且つ溶媒化され圧縮されたタンパク質マトリックス材料形成するように圧縮されている、タンパク質マトリックス材料。
【請求項２】 塗布可能なフィルムを形成するように１又は複数の生物適合性溶媒と組み合わされた１又は複数の生物適合性タンパク質材料を含んで成る溶媒化された接着性タンパク質体であって、前記の塗布可能なフィルムが部分的に乾燥され、そして溶媒化された接着体に形成されているタンパク質体。
【請求項３】 溶媒化され、圧縮されたタンパク質マトリックス材料の製造方法において、
（ａ）１又は複数の生適合性タンパク質材料および１又は複数の生適合性溶媒を含む塗布可能な組成物を調製し、
（ｂ）前記組成物を塗布して皮膜を形成し、
（ｃ）塗布皮膜が接着性体に形成されるまで前記塗布皮膜を部分的に乾燥し、
（ｄ）前記接着性体を形成し、そして前記接着性体を圧縮してタンパク質マトリックス材料を生成する、
ことを含んで成る方法。
【請求項４】 前記生物適合性タンパク質が、エラスチン、コラーゲン、アルブミン、ケラチン、フィブロネクチン、シルク、シルクフィブロイン、アクチン、ミオシン、フィブリノーゲン、トロンビン、アプロチニン、アンチトロンビンIII 、エラスチン様ブロック、シルク様ブロック、コラーゲン様ブロック、ラミニン様ブロック，フィブロネクチン様ブロック、シルク様およびエラスチン様ブロック、コラーゲン−へパリン、及びコラーゲン−コンドロイチンから成る群から選択される、請求項１に記載のタンパク質マトリックス材料、請求項２に記載のタンパク質体又は請求項３に記載の方法。
【請求項５】 前記生適合性溶媒が、水、ジメチルスルホキシド（DMSO）、生体適合性アルコール、生体適合性酸、油および生適合性グリコールから成る群から選択される、請求項１又は４に記載のタンパク質マトリックス材料、請求項２又は４に記載のタンパク質体、或いは請求項３又は４に記載の方法。
【請求項６】 前記タンパク質マトリックス材料が、１または複数の薬理学的活性剤、好ましくは鎮痛薬、麻酔薬、抗精神病薬、ステロイド、抗ステロイド、コルチコステロイド、抗緑内障薬、抗アルコール薬、抗凝固薬、遺伝子物質、抗血栓崩壊薬、抗癌薬、抗パーキンソン薬、鎮痙薬、抗炎症薬、避妊薬、酵素剤、細胞、増殖因子、抗ウイルス薬、抗細菌薬、抗真菌薬、低血糖薬、抗ヒスタミン薬、化学誘引物質、neutraceuticals、抗肥満薬、喫煙停止薬、助産薬および抗喘息薬から成る群から選択される薬理学的活性剤を更に含む、請求項１、４又は５に記載のタンパク質マトリックス材料、請求項２、４又は５に記載のタンパク質体、或いは請求項３、４又は５に記載の方法。
【請求項７】 前記薬理学的活性剤が、二次易移動性薬剤送達装置を含む、請求項６に記載のタンパク質マトリックス材料、タンパク質体、或いは方法。
【請求項８】 １つまたは複数の生物適合性高分子材料をさらに含む、請求項１、４〜７のいずれか１項に記載のタンパク質マトリックス材料、請求項２、４〜７のいずれか１項に記載のタンパク質体、或いは請求項３、４〜７のいずれか１項に記載の方法。
【請求項９】 前記１つまたは複数の生物適合性高分子物質が、エポキシ樹脂、ポリエステル樹脂、アクリル樹脂、ナイロン樹脂、シリコーン樹脂、ポリ無水物、ポリウレタン樹脂、ポリカルボネート、ポリ（テトラフルオロエチレン）、ポリカプロラクトン、ポリエチレンオキシド、ポリエチレングリコール、ポリ（ビニルクロリド）、ポリ乳酸、ポリグリコール酸、ポリプロピレンオキシド、ポリ（アルキレン）グリコール、ポリオキシエチレン、セバシン酸、ポリビニルアルコール、２−ヒドロキシエチルメタクリレート、ポリメチルメタクリレート、１，３−ビス（カルボキシフェノキシ）プロパン、脂質、ホスファチジルコリン、トリグリセリド、ポリヒドロキシブチレート、ポリヒドロキシバレレート、ポリ（エチレンオキシド）、ポリオルトエステル、ポリ（アミノ酸）、ポリシノアクリレート、ポリホスファゼン、ポリスルホン、ポリアミン、ポリ（アミドアミン）、フィブリン、グラファイト、軟質フルオロポリマー、イソブチルベース物質、イソプロピルスチレン、ビニルピロリドン、セルロースアセテートジブチレート、シリコーンゴムおよびこれらのコポリマーから成る群から選択される請求項８記載の、タンパク質マトリックス材料、タンパク質体、或いは方法。
【請求項１０】 前記タンパク質マトリックス物質が１つまたは複数の架橋剤により架橋され、当該架橋試薬が、好ましくは、グルタルアルデヒド、ｐ−アジドベンゾイルヒダジド、Ｎ−５−アジド−２−ニトロベンゾイルオキシスクシンイミド、Ｎ−スクシンイミジル６−［４’アジド−２’ニトロ−フェニルアミノ］ヘキサノエートおよび４−［ｐ−アジドサリチルアミド］ブチルアミンから成る群から選択される、請求項１、４〜９のいずれか１項に記載のタンパク質マトリックス材料、或いは請求項２、４〜９いずれか１項に記載のタンパク質体。
【請求項１１】 前記マトリックス材料が、マスキング又はUV光活性化剤を用いて、予め定められたパターンに架橋することによりプリントされる、請求項１、４〜10のいずれか１項に記載のタンパク質マトリックス材料。
【請求項１２】 前記タンパク質マトリックス材料が、シリンダー、キューブ、球、挿入材、メッシュ、ストリップ、縫合、プラグ、包帯、ディスク、関節、出口封止材、チューブ、粒子、シート、ウエファー、糸及びパッチからなる群から選択される形態で製造される、請求項１、４〜10のいずれか１項に記載のタンパク質マトリックス材料。
【請求項１３】 前記タンパク質マトリックス材料が、タンパク質マトリックス材料の２以上の層を含む、請求項１、４〜10のいずれか１項に記載のタンパク質マトリックス材料。
【請求項１４】 前記タンパク質マトリックス材料を１又は複数の架橋剤により架橋する工程を含んで成る、請求項３〜９の何れか１項に記載のタンパク質マトリックス材料の製造方法。
【請求項１５】 請求項１、４〜10のいずれか１項に記載の溶媒化され圧縮されたタンパク質マトリックス材料を含んでなる、溶媒化され圧縮された薬剤供給装置。
【請求項１６】 シリンダー、キューブ、粒子、シート、ウエファ、糸及びパッチからなる群から選択される形態で製造される、請求項15に記載の溶媒化され圧縮された薬剤供給装置。
【請求項１７】 外部刺激との接触の後に前記薬理学的活性剤を放出する放出機構を更に有する、請求項15又は16に記載の薬剤供給装置。
【請求項１８】 １又は複数のタンパク質マトリックス材料の１又は複数の層を含む、請求項15〜17のいずれか１項に記載の薬剤供給装置。
【請求項１９】 請求項１、４〜10、12及び13のいずれか１項に記載の溶媒化され圧縮されたタンパク質マトリックス材料を含んでなる圧縮されている創傷治癒装置。
【請求項２０】 骨挿入物、メッシュ、ストリップ、縫合、歯科用プラグ、皮膚包帯、帯具、組織プラグ、脊椎挿入物、椎間円板、関節、気管支組織挿入物、腹部挿入物、血管挿入物、粒子、生物学的ファッスナー、ステップル、止血材および出入口封止装置から成る群から選択される、請求項19に記載の創傷治癒装置。
【請求項２１】 付着性末端に隣接した非付着性ストリップ上に置かれたタンパク質マトリックス物質のセグメントを含む請求項20に記載の創傷治癒装置。
【請求項２２】 骨挿入物、メッシュ、ストリップ、縫合、歯科用プラグ、皮膚包帯、帯具、組織プラグ、脊椎挿入物、椎間円板、関節、気管支組織挿入物、腹部挿入物、血管挿入物、粒子、生物学的ファッスナー、ステップル、止血材又は出入口封止装置の後に連結された、追加の医薬活性剤の供給のためのパッチ供給システムを含む、請求項20に記載の創傷治癒装置。
【請求項２３】 １又は複数のタンパク質マトリックス材料の１又は複数の層を含む、請求項19又は20に記載の創傷治癒装置。
【請求項２４】 請求項１、４〜10、12及び13からなる群から選択される溶媒化され圧縮されたタンパク質マトリックス材料を含んでなる、溶媒化され圧縮された組織移植片。
【請求項２５】 血管、管状移植片、気管チューブ、気管支チューブ、カテーテル機能チューブ、肺移植片、胃腸セグメント、透明マトリックス移植片、心臓弁、軟骨、腱、靭帯、皮膚移植片、粒子、骨挿入物、メッシュ、ストリップ、縫合、歯科用プラグ、組織プラグ、脊椎挿入物、椎間円板、関節、気管支組織挿入物、腹部挿入物、血管挿入物、び出入口封止装置及び膵臓移植装置から成る群から選択される請求項24に記載の組織移植片。
【請求項２６】 １又は複数のタンパク質マトリックス材料の１又は複数の層を含む、請求項24又は25に記載の組織移植片。
【請求項２７】 請求項１、４〜10、12及び13からなる群から選択される溶媒化され圧縮されたタンパク質マトリックス材料を含んでなる、溶媒化され圧縮されたステント被覆。
【請求項２８】 １又は複数のタンパク質マトリックス材料の１又は複数の層を含む、請求項27に記載のステント被覆。
【請求項２９】 請求項１、４〜10、12及び13からなる群から選択される溶媒化され圧縮されたタンパク質マトリックス材料を含んでなる、溶媒化され圧縮されているタンパク質マトリックスIUD。
【請求項３０】 請求項１、４〜10、12及び13からなる群から選択される溶媒化され圧縮されたタンパク質マトリックス材料を含んでなる、溶媒化され圧縮されたイメージマーカー。
[Claims]
1. A solvated, compressed protein matrix material comprising one or more biocompatible protein materials combined with one or more biocompatible solvents to form a coatable film. Wherein said coatable film is partially dried, formed into an adherent, and compressed to reduce bulk water and form a solvated, compressed protein matrix material.
2. A solvated adhesive protein body comprising one or more biocompatible protein materials combined with one or more biocompatible solvents to form a coatable film. A protein body wherein said coatable film has been partially dried and formed into a solvated adhesive.
3. A method for producing a solvated and compressed protein matrix material, comprising:
(A) preparing a coatable composition comprising one or more biocompatible protein materials and one or more biocompatible solvents;
(B) applying the composition to form a film;
(C) partially drying the coating film until the coating film is formed on the adhesive body,
(D) forming the adhesive and compressing the adhesive to produce a protein matrix material;
A method comprising:
4. The method according to claim 1, wherein the biocompatible protein is elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin, antithrombin III, elastin-like block, silk-like block, collagen. The protein matrix material according to claim 1, wherein the protein matrix material is selected from the group consisting of block-like blocks, laminin-like blocks, fibronectin-like blocks, silk-like and elastin-like blocks, collagen-heparin, and collagen-chondroitin. 4. The method of claim 3, wherein
5. The method according to claim 1, wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), a biocompatible alcohol, a biocompatible acid, an oil and a biocompatible glycol. The protein matrix material according to claim 2, the protein body according to claim 2 or 4, or the method according to claim 3 or 4.
6. The method of claim 1, wherein the protein matrix material comprises one or more pharmacologically active agents, preferably analgesics, anesthetics, antipsychotics, steroids, antisteroids, corticosteroids, antiglaucoma drugs, antialcoholic drugs, Anticoagulants, genetic substances, antithrombolytics, anticancer drugs, antiparkinsonian, antispasmodic, antiinflammatory, contraceptives, enzymatics, cells, growth factors, antivirals, antibacterials, antifungals, 5. The method according to claim 1, further comprising a pharmacologically active agent selected from the group consisting of hypoglycemic drugs, antihistamines, chemoattractants, neutraceuticals, antiobesity drugs, smoking cessation drugs, midwifery drugs and antiasthmatic drugs. The protein matrix material according to claim 5, the protein body according to claim 2, 4 or 5, or the method according to claim 3, 4 or 5.
7. The protein matrix material, protein body, or method of claim 6, wherein the pharmacologically active agent comprises a secondary mobile drug delivery device.
8. The protein matrix material according to claim 1, further comprising one or more biocompatible polymeric materials, and the protein matrix material according to any one of claims 2, 4 to 7. The protein body according to claim or the method according to any one of claims 3, 4 to 7.
9. The method according to claim 1, wherein the one or more biocompatible polymer substances are epoxy resin, polyester resin, acrylic resin, nylon resin, silicone resin, polyanhydride, polyurethane resin, polycarbonate, poly (tetrafluoroethylene). ), Polycaprolactone, polyethylene oxide, polyethylene glycol, poly (vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly (alkylene) glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, poly Methyl methacrylate, 1,3-bis (carboxyphenoxy) propane, lipid, phosphatidylcholine, triglyceride, polyhydroxybutyrate, polyhydroxyvalerate, poly (ethylene oxide) , Polyorthoesters, poly (amino acids), polysinoacrylates, polyphosphazenes, polysulfones, polyamines, poly (amidoamines), fibrin, graphite, soft fluoropolymers, isobutyl-based substances, isopropylstyrene, vinylpyrrolidone, cellulose acetate dibutyrate, silicone 9. The protein matrix material, protein body, or method of claim 8, selected from the group consisting of rubber and copolymers thereof.
10. The protein matrix material is cross-linked by one or more cross-linking agents, wherein the cross-linking reagent is preferably glutaraldehyde, p-azidobenzoyl hidazide, N-5-azido-2-nitrobenzoyloxy. The succinimide, N-succinimidyl 6- [4'azido-2'nitro-phenylamino] hexanoate and 4- [p-azidosalicylamido] butylamine are selected from the group consisting of: The protein matrix material according to claim 1 or the protein body according to any one of claims 2, 4 to 9.
11. The method according to claim 1, wherein the matrix material is printed by crosslinking in a predetermined pattern using a masking or UV light activator. Protein matrix material.
12. The protein matrix material may be a cylinder, cube, sphere, insert, mesh, strip, suture, plug, bandage, disk, joint, outlet seal, tube, particle, sheet, wafer, thread, and patch. The protein matrix material according to any one of claims 1, 4 to 10, wherein the protein matrix material is manufactured in a form selected from the group consisting of:
13. The protein matrix material according to claim 1, wherein the protein matrix material comprises two or more layers of the protein matrix material.
14. The method for producing a protein matrix material according to claim 3, comprising a step of crosslinking the protein matrix material with one or more crosslinking agents.
15. A solvated and compressed drug delivery device comprising a solvated and compressed protein matrix material according to any one of claims 1, 4 to 10.
16. The drug delivery device of claim 15, wherein the drug delivery device is manufactured in a form selected from the group consisting of cylinders, cubes, particles, sheets, wafers, threads, and patches.
17. The drug delivery device according to claim 15, further comprising a release mechanism that releases the pharmacologically active agent after contact with an external stimulus.
18. The drug delivery device according to any one of claims 15 to 17, comprising one or more layers of one or more protein matrix materials.
19. A compressed wound healing device comprising a solvated compressed protein matrix material according to any one of claims 1, 4 to 10, 12 and 13.
20. Bone insert, mesh, strip, suture, dental plug, skin bandage, bandage, tissue plug, spinal insert, intervertebral disc, joint, bronchial tissue insert, abdominal insert, vascular insert 20. The wound healing device of claim 19, wherein the wound healing device is selected from the group consisting of an object, a particle, a biological fastener, a stapler, a hemostat, and a port closure device.
21. The wound healing device according to claim 20, comprising a segment of protein matrix material placed on a non-adherent strip adjacent to an adherent end.
22. Bone insert, mesh, strip, suture, dental plug, skin dressing, bandage, tissue plug, spinal insert, intervertebral disc, joint, bronchial tissue insert, abdominal insert, vascular insert 21. The wound healing device of claim 20, comprising a patch delivery system for delivery of an additional pharmaceutically active agent, connected after the object, particle, biological fastener, stapler, hemostat or port closure device.
23. The wound healing device according to claim 19 or 20, comprising one or more layers of one or more protein matrix materials.
24. A solvated and compressed tissue graft comprising a solvated and compressed protein matrix material selected from the group consisting of: 1, 4-10, 12 and 13.
25. Blood vessels, tubular grafts, tracheal tubes, bronchial tubes, catheter function tubes, lung grafts, gastrointestinal segments, transparent matrix grafts, heart valves, cartilage, tendons, ligaments, skin grafts, particles, bone inserts Objects, meshes, strips, sutures, dental plugs, tissue plugs, spinal inserts, intervertebral discs, joints, bronchial tissue inserts, abdominal inserts, vascular inserts, vent seals and pancreas implants 25. The tissue graft of claim 24 selected from the group.
26. The tissue implant of claim 24 or 25, comprising one or more layers of one or more protein matrix materials.
27. A solvated and compressed stent coating comprising a solvated and compressed protein matrix material selected from the group consisting of: 1, 4-10, 12 and 13.
28. The stent coating of claim 27, comprising one or more layers of one or more protein matrix materials.
29. A solvated and compressed protein matrix IUD comprising a solvated and compressed protein matrix material selected from the group consisting of: 1, 4-10, 12 and 13.
30. A solvated and compressed image marker comprising a solvated and compressed protein matrix material selected from the group consisting of: 1, 4-10, 12 and 13.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18542000P | 2000-02-28 | 2000-02-28 | |
| US60/185,420 | 2000-02-28 | ||
| US22276200P | 2000-08-03 | 2000-08-03 | |
| US60/222,762 | 2000-08-03 | ||
| PCT/US2001/006502 WO2001087267A1 (en) | 2000-02-28 | 2001-02-28 | Protein matrix materials, devices and methods of making and using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003533468A JP2003533468A (en) | 2003-11-11 |
| JP2003533468A5 true JP2003533468A5 (en) | 2008-04-24 |
Family
ID=26881122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001583736A Pending JP2003533468A (en) | 2000-02-28 | 2001-02-28 | Protein matrix materials, production and their production and use |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1259223A4 (en) |
| JP (1) | JP2003533468A (en) |
| AU (2) | AU4907901A (en) |
| CA (1) | CA2401385C (en) |
| WO (1) | WO2001087267A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US20030007991A1 (en) * | 1998-09-25 | 2003-01-09 | Masters David B. | Devices including protein matrix materials and methods of making and using thereof |
| US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
| US20050147690A1 (en) * | 1998-09-25 | 2005-07-07 | Masters David B. | Biocompatible protein particles, particle devices and methods thereof |
| US20020156437A1 (en) * | 2000-12-22 | 2002-10-24 | Kimberly-Clark Worldwide, Inc. | Removal of targeted proteases with proteinaceous wound dressings containing growth factors |
| US6444222B1 (en) * | 2001-05-08 | 2002-09-03 | Verigen Transplantation Services International Ag | Reinforced matrices |
| EP1434571B1 (en) | 2001-10-05 | 2005-05-11 | SurModics, Inc. | Particle immobilized coatings and uses thereof |
| US6902932B2 (en) * | 2001-11-16 | 2005-06-07 | Tissue Regeneration, Inc. | Helically organized silk fibroin fiber bundles for matrices in tissue engineering |
| EP1576969B1 (en) * | 2001-12-21 | 2018-08-15 | Coloplast A/S | A wound care device |
| AU2003225212A1 (en) | 2002-04-29 | 2003-11-17 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
| JP2006500975A (en) * | 2002-08-02 | 2006-01-12 | ジーピー メディカル | Drug-carrying biomaterials chemically treated with genipin |
| CA2501298A1 (en) * | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
| JP2006505364A (en) * | 2002-11-08 | 2006-02-16 | コナー メドシステムズ， インコーポレイテッド | Expandable medical device and method for treating chronic total infarction using a local supply of angiogenic factors |
| EP1894945B1 (en) * | 2003-03-28 | 2009-12-02 | FUJIFILM Manufacturing Europe B.V. | RGD-enriched gelatine-like proteins with enhanced cell binding |
| WO2004104021A2 (en) * | 2003-05-14 | 2004-12-02 | Dow Corning Corporation | Controlled release of active agents utilizing repeat sequence protein polymers |
| US8465537B2 (en) | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
| US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
| CA2537315C (en) | 2003-08-26 | 2015-12-08 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
| EP1691746B1 (en) | 2003-12-08 | 2015-05-27 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
| KR20070009565A (en) * | 2004-01-23 | 2007-01-18 | 캘리포니아 인스티튜트 오브 테크놀로지 | Engineered proteins, and methods of making and using |
| EP1773240B1 (en) * | 2004-06-11 | 2019-11-20 | Trustees of the Tufts College | Silk-based drug delivery system |
| US20060067971A1 (en) * | 2004-09-27 | 2006-03-30 | Story Brooks J | Bone void filler |
| EP1986611B1 (en) * | 2006-02-23 | 2013-05-01 | Danisco US Inc. | Repeat sequence protein polymer nanoparticles optionally containing active agents and their preparation |
| US9050402B2 (en) * | 2006-03-14 | 2015-06-09 | Kci Licensing, Inc. | Method for percutaneously administering reduced pressure treatment using balloon dissection |
| EP2237770A4 (en) | 2007-12-26 | 2011-11-09 | Gel Del Technologies Inc | Biocompatible protein particles, particle devices and methods thereof |
| CN101221180B (en) * | 2008-01-25 | 2011-11-30 | 马义才 | Portable fast joint inspection device for multiple tumor marker |
| WO2010026760A1 (en) * | 2008-09-03 | 2010-03-11 | 富士フイルム株式会社 | Compositions wherein bioactive components are stably sealed |
| WO2010057177A2 (en) | 2008-11-17 | 2010-05-20 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
| US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| US20110060419A1 (en) * | 2009-03-27 | 2011-03-10 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
| JP2012528149A (en) | 2009-05-28 | 2012-11-12 | アドビオ・アーベー | Multilayer protein film, method for producing the film, and drug delivery device and medical implant using the film |
| EP2776079B1 (en) * | 2011-11-09 | 2020-04-01 | Trustees Of Tufts College | Injectable silk fibroin foams and uses thereof |
| CA2867464A1 (en) * | 2012-03-20 | 2013-09-26 | Trustees Of Tufts College | Silk reservoirs for drug delivery |
| DK2830595T3 (en) | 2012-03-29 | 2019-12-02 | Translate Bio Inc | IONIZABLE CATIONIC LIPIDS |
| US8691915B2 (en) | 2012-04-23 | 2014-04-08 | Sabic Innovative Plastics Ip B.V. | Copolymers and polymer blends having improved refractive indices |
| WO2018081805A1 (en) | 2016-10-31 | 2018-05-03 | Sofregen Medical, Inc. | Compositions comprising low molecular weight silk fibroin fragments and plasticizers |
| CN108310455B (en) * | 2018-03-20 | 2021-07-30 | 嘉兴尔云信息科技有限公司 | Nano hydroxyapatite and PGS-M composite bone repair material and preparation method thereof |
| CN108926744A (en) * | 2018-09-13 | 2018-12-04 | 广州贝奥吉因生物科技有限公司 | A kind of compound rest and preparation method thereof for repair of cartilage |
| EP4045124A4 (en) | 2019-10-15 | 2024-01-24 | Sofregen Medical Inc | Delivery devices for delivering and methods of delivering compositions |
| TWI763265B (en) * | 2021-01-20 | 2022-05-01 | 巴斯特製藥科技顧問股份有限公司 | An organ-repairing membrane with structural proteins and use thereof |
| CN114354585B (en) * | 2021-11-09 | 2023-09-26 | 北京航空航天大学 | Horseradish peroxidase composite gel photonic crystal sensor and method |
| CN114505070B (en) * | 2022-04-02 | 2024-02-02 | 陕西师范大学 | Porous nano-enzyme, porous nano-enzyme crystal, preparation method and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
| JPH05192387A (en) * | 1990-11-08 | 1993-08-03 | Matrix Pharmaceut Inc | Fibrin for biomedical purpose/ collagenic coat |
| CA2089487A1 (en) * | 1991-06-14 | 1992-12-15 | Suk-Zu Song | Collagen film drug delivery for proteins |
| CA2117780A1 (en) * | 1992-04-10 | 1993-10-28 | Paul F. Goetinck | Cartillage matrix protein and methods for use |
| AU7568394A (en) * | 1993-08-19 | 1995-03-14 | Cygnus Therapeutic Systems | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
| US5783214A (en) * | 1994-06-13 | 1998-07-21 | Buford Biomedical, Inc. | Bio-erodible matrix for the controlled release of medicinals |
| CN1052915C (en) * | 1995-11-27 | 2000-05-31 | 中国医学科学院生物医学工程研究所 | Medical carrier of protein coat for carrying gene and its prodn. method |
| EP0914168A1 (en) * | 1996-05-03 | 1999-05-12 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| US6221425B1 (en) * | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
| GB9806966D0 (en) * | 1998-03-31 | 1998-06-03 | Ppl Therapeutics Scotland Ltd | Bioloically modified device |
| US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| JP4332660B2 (en) * | 1999-10-01 | 2009-09-16 | Ｏｃｉ株式会社 | Mouth cool film |
-
2001
- 2001-02-28 EP EP01922258A patent/EP1259223A4/en not_active Ceased
- 2001-02-28 JP JP2001583736A patent/JP2003533468A/en active Pending
- 2001-02-28 AU AU4907901A patent/AU4907901A/en active Pending
- 2001-02-28 CA CA2401385A patent/CA2401385C/en not_active Expired - Fee Related
- 2001-02-28 WO PCT/US2001/006502 patent/WO2001087267A1/en active IP Right Grant
- 2001-02-28 AU AU2001249079A patent/AU2001249079B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003533468A5 (en) | ||
| CA2401385A1 (en) | Protein matrix materials, devices and methods of making and using thereof | |
| EP1778144B1 (en) | Anti-adhesion barrier | |
| US7662409B2 (en) | Protein matrix materials, devices and methods of making and using thereof | |
| US20190125928A1 (en) | Protein biomaterials and biocoacervates and methods of making and using thereof | |
| CA2583561C (en) | Biocompatible protein particles, particle devices and methods thereof | |
| JP2020058884A (en) | Particulate tissue graft having components with different densities and method for manufacturing and using the same | |
| EP0888140B1 (en) | Coated bioabsorbable beads for wound treatment | |
| EP1328300B1 (en) | Self-adhesive hydratable matrix for topical therapeutic use | |
| US9393347B2 (en) | Double-structured tissue implant and a method for preparation and use thereof | |
| US20030133967A1 (en) | Multilayer collagen matrix for tissue reconstruction | |
| US20020085994A1 (en) | A trilayered collagen construct | |
| AU2001249079A1 (en) | Protein matrix materials, devices and methods of making and using thereof | |
| WO2005018491A2 (en) | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof | |
| CA2536104A1 (en) | Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods forpreparation and use thereof | |
| AU2005244692B2 (en) | Tissue closing preparation | |
| JP5374496B2 (en) | Medical composition | |
| WO2019222520A1 (en) | Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation | |
| AU2004279349B2 (en) | Protein biomaterials and biocoacervates and methods of making and using thereof |